Kexing Biopharm's Albumin-Bound Paclitaxel Product Approved in Multiple Regions

Article source：Mar 10,2026View： 292

Recently, Kexing Biopharm’s overseas commercial product Paclitaxel for Injection (Albumin Bound) (Apexelsin®),  has received marketing authorization in Macao (China) and Malaysia. Apexelsin® has achieved multiple critical milestones in global market access, further expanding marketable regions and injecting robust momentum into the Company's global pharmaceutical market development.

Paclitaxel for Injection (Albumin Bound) is primarily used to treat various malignant tumors such as metastatic breast cancer, non-small cell lung cancer, and metastatic pancreatic cancer. Its formulation offers clinical advantages, with enhanced safety, patient compliance, and high clinical recognition.

Additionally, Kexing Biopharm's proprietary human erythropoietin (EPO) and the overseas commercial product oral antidiabetic drug Sitagliptin have also been approved for marketing in Macao (China), enriching the Company's product portfolio in the Macao market.

Since the beginning of 2026, the advancement of the Company's "Innovation + Internationalization" strategy has continued to accelerate. In the future, Kexing Biopharm will continue to uphold the philosophy of "Precise Products, Predictable Effects, Health Protection", serving patients worldwide.